Gamma Frequency Sensory Stimulation for Alzheimer's Disease

(GENUS Trial)

This trial aims to test a new device called GENUS to determine if it can slow memory and thinking problems in people with Alzheimer's disease. The device uses a type of brain stimulation to assess its effects on brain activity and safety. Participants will visit MIT for one day to undergo various tests, including brain scans and memory tests. The trial suits those who are healthy, have no history of seizures, and do not have metal implants that could interfere with MRI scans. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants the chance to contribute to important advancements in Alzheimer's care.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators for more details.

Research has shown that GENUS, a device using 40Hz sound and light stimulation, is generally safe for people. Studies have found that most individuals tolerate this treatment well without serious side effects. Some mild issues, such as dizziness, headaches, or ringing in the ears, have been reported, but these are uncommon. One study found that using GENUS daily for up to two years is safe and doesn't cause major problems. This suggests that GENUS could be a suitable option for those considering participation in a clinical trial.¹²³⁴⁵

Most treatments for Alzheimer's disease focus on managing symptoms or slowing progression through medication, like cholinesterase inhibitors and memantine. However, GENUS (Gamma ENtrainment Using Sensory) is unique because it targets the brain's gamma frequency oscillations, which are believed to be disrupted in Alzheimer's patients. This non-invasive technique uses sensory stimulation, like light and sound, to potentially restore these brain rhythms. Researchers are excited about GENUS because it offers a novel approach that could improve cognitive function by addressing the underlying neural activity, rather than just alleviating symptoms.

Research has shown that GENUS, a treatment using specific sound and light patterns, may aid in managing Alzheimer's disease. Studies have found that 40 Hz stimulation can reduce harmful brain proteins, such as amyloid and tau. Other research indicates that GENUS can enhance memory and cognitive skills. Some trials reported improvements in sleep and daily functioning after several weeks of treatment. These findings suggest that GENUS might slow memory and cognitive decline in Alzheimer's patients. Participants in this trial will receive GENUS to further evaluate its effects.¹³⁶⁷⁸